AC
ACRS.O
—
NASDAQ
Pharmaceuticals
Acrs.O
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
666,4M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
-975,9 %
ROE
-63,0 %
Net margin
-829,6 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$5,32
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Aclaris Therapeutics Inc operates in the Health Care sector, specifically within Pharmaceuticals, though its specific business activity remains unclassified in the available data.
Business. Aclaris Therapeutics Inc operates in the Health Care sector, specifically within Pharmaceuticals, though its specific business activity remains unclassified in the available data.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY10 analysts
9 buy1 hold0 sell
Avg 12m price target8,61
Analyst recommendations
10 analysts · consensus BuyBuy9
Hold1
Sell0
12-month price target
8,61
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
10 analysts · indicative
Ownership→
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability→
-63,0 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ACRS.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Aclaris Therapeutics Inc operates in the Health Care sector, specifically within Pharmaceuticals, though its specific business activity remains unclassified in the available data.
Classification85 %
SectorHealth Care
Industry groupPharmaceuticals
AI synthesis
GENERATED(a) Capital structure and liquidity: The company maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0, supported by total equity of $103.1 million against total liabilities of $57.4 million. Cash and equivalents stand at $19.96 million, which is modest relative to the burn rate implied by negative operating cash flow of $47.1 million. The current ratio is not explicitly provided, but the absence of debt suggests low immediate solvency risk, although the liquidity risk assessment is flagged as "low" in the risk module, likely referring to the low level of risk rather than low liquidity, or potentially indicating tight liquidity given the cash position versus burn. The market capitalization is $612.1 million, trading at a price-to-book ratio of 5.94, indicating the market values the company significantly above its tangible book value.
(b) Profitability and returns: The company is not yet profitable, reporting a net loss of $64.9 million on revenue of $7.8 million. This results in a negative return on equity of -62.98% and a negative return on assets of -40.46%. The operating income is -$76.4 million, highlighting significant operational losses relative to the small revenue base. The EV/EBITDA ratio is negative at -7.75, and the EV/Revenue ratio is extremely high at 75.66, reflecting the pre-commercial or early-commercial stage nature of the business where investors are pricing in future potential rather than current earnings.
Key takeaways
- The company is debt-free with a strong equity base, but burns cash significantly, with operating cash flow of -$47.1 million.
- Valuation multiples are extremely high (EV/Revenue 75.66), reflecting pre-profitability status and market expectations for future growth.
- Analyst sentiment is strongly positive, with a mean recommendation of 1.60 and a mean price target of $8.61, implying ~70% upside.
- Profitability is negative with a net loss of $64.9 million, resulting in negative ROE and ROA.
- No specific segment or geographic data is available, limiting detailed concentration risk analysis.
- Risk assessment flags low liquidity and dilution risk, but the high cash burn rate poses a fundamental operational risk.
Bull / Bear case
analysis pipeline— missing data
In focus — financials by report
Valuation
Market price
$5,53
Market cap
$612.1M
Enterprise valueⓘ
$592.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
5.9x
P / Tangible bookⓘ
5.9x
Tangible book
$103.1M
Net cashⓘ
$20.0M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-40.5%
ROEⓘ
-63.0%
Cash conversionⓘ
73.0%
CapEx / revenueⓘ
1.4%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,64
Predicted surprise
+0,00
Beat probability
45 %
Analysts
10
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-08-02 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,65 |
| Revenue | —no estimate | —no estimate | 6,3M USD |
| Operating income | —no estimate | —no estimate | -91,3M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution12 analysts
Strong buy6
Buy5
Hold1
Sell0
Strong sell0
12-month price target$9,77 · Median $10,00
Low $4,00High $16,00
Operating income · consensus-91,3M USD
EPS surprise
+18,3 %
reported vs consensus · beat
Revenue surprise
+24,1 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$3,00
Mean$8,61
Median$7,50
High$16,00
Spot$5,53
+55.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-975,9 %Bottom quartile
Net Margin-829,6 %Bottom quartile
ROE-63,0 %Bottom quartile
Capex / Rev1,4 %Above P75
D/E0,00Above P75
Cash Conv0,73Below median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 3 256 142 sh20 exercises · 24 grants12 insiders
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Restricted Stock Units → Common StockDisposed 11 580exercise · 2026-06-05
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Stock Option (Right to Buy) → Common StockAcquired 42 350 @ $4,71grant · 2026-06-04
- Director · Restricted Stock Units → Common StockAcquired 10 987grant · 2026-06-04
- Chief Medical Officer · Restricted Stock Units → Common StockDisposed 36 375exercise · 2026-05-01
- Chief Financial Officer · Restricted Stock Units → Common StockDisposed 2 375exercise · 2026-03-01
- Director, President and COO · Restricted Stock Units → Common StockDisposed 18 675exercise · 2026-02-03
- Chief Financial Officer · Restricted Stock Units → Common StockDisposed 22 025exercise · 2026-02-03
- Director, CEO · Restricted Stock Units → Common StockDisposed 63 475exercise · 2026-02-03
- Chief Business Officer · Restricted Stock Units → Common StockDisposed 20 875exercise · 2026-02-03
- Chief Business Officer · Employee Stock Option (Right to Buy) → Common StockAcquired 341 900 @ $3,61grant · 2026-02-02
Actions
Ask Handelsavisen
— missing data
Data sources
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
Source documents
- Aclaris Therapeutics, Inc. Market data — financials · 2026-08-02
- reconciler_enqueue (reconciler) on ACRS.O · 2026-08-02
- Aclaris Therapeutics Inc Market data — analyst estimates · 2026-08-02
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$3M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2025-12-310,00 %$20M
- Investment Managers · as of 2026-03-310,00 %$8M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$2M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net selling0 buys · 1 sellsnet -$1,4M12 insiders · last 365d
- Director · Common StockOther 11 580 · 2026-06-05
- Director · Common StockOther 11 580 · 2026-06-05
- Director · Common StockOther 11 580 · 2026-06-05
- Director · Common StockOther 11 580 · 2026-06-05
- Director · Common StockOther 11 580 · 2026-06-05
- Director · Common StockOther 11 580 · 2026-06-05
- Chief Medical Officer · Common StockOther 9 330 @ $4,41$41K · 2026-05-01
- Chief Medical Officer · Common StockOther 36 375 · 2026-05-01
- 10% owner · Common StockSold 300 000 @ $4,53$1,4M · 2026-04-23
- Chief Financial Officer · Common StockOther 677 @ $2,87$2K · 2026-03-01
- Chief Financial Officer · Common StockOther 2 375 · 2026-03-01
- Chief Business Officer · Common StockOther 20 875 · 2026-02-03
- Chief Business Officer · Common StockOther 5 937 @ $3,47$21K · 2026-02-03
- Director, CEO · Common StockOther 63 475 · 2026-02-03
- Director, CEO · Common StockOther 18 611 @ $3,47$65K · 2026-02-03
- Director, President and COO · Common StockOther 18 675 · 2026-02-03
- Chief Financial Officer · Common StockOther 22 025 · 2026-02-03
- Chief Financial Officer · Common StockOther 6 449 @ $3,47$22K · 2026-02-03
- Chief Financial Officer · Common StockOther 4 984 @ $3,51$17K · 2026-02-01
- Chief Financial Officer · Common StockOther 14 750 · 2026-02-01
- Chief Financial Officer · Common StockOther 4 461 @ $2,88$13K · 2026-01-02
- Director, CEO · Common StockOther 29 150 · 2026-01-02
- Director, CEO · Common StockOther 9 952 @ $2,88$29K · 2026-01-02
- Chief Business Officer · Common StockOther 6 171 @ $2,88$18K · 2026-01-02
- Chief Business Officer · Common StockOther 18 150 · 2026-01-02
Short positioning
13.4Mshares short+17.1% vs prior
6.92days to cover
62.2%short of daily vol
45fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ACRS.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data— missing data
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-05 00:00 UTCINSIDER24 insider transactions — 2026-06 18 derivative
2026-06-05INSIDERSCHIFF ANDREW N transacted 11.6k sh — Director
2026-06-05INSIDERMILANO VINCENT transacted 11.6k sh — Director
2026-06-05INSIDERMehra Anand transacted 11.6k sh — Director
2026-06-05INSIDERGOWEN MAXINE transacted 11.6k sh — Director
2026-06-05INSIDERHumphries William D. transacted 11.6k sh — Director
2026-06-05INSIDERMolineaux Christopher P. transacted 11.6k sh — Director
2026-06-05INSIDERMehra Anand disposed of 11.6k sh Restricted Stock Units — Director
2026-06-05INSIDERSCHIFF ANDREW N disposed of 11.6k sh Restricted Stock Units — Director
2026-06-05INSIDERGOWEN MAXINE disposed of 11.6k sh Restricted Stock Units — Director
2026-06-05INSIDERHumphries William D. disposed of 11.6k sh Restricted Stock Units — Director
2026-06-05INSIDERMolineaux Christopher P. disposed of 11.6k sh Restricted Stock Units — Director
2026-06-05INSIDERMILANO VINCENT disposed of 11.6k sh Restricted Stock Units — Director
2026-06-04INSIDERGOWEN MAXINE acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERMILANO VINCENT acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERMILANO VINCENT acquired 11.0k sh Restricted Stock Units — Director
2026-06-04INSIDERGOWEN MAXINE acquired 11.0k sh Restricted Stock Units — Director
2026-06-04INSIDERMolineaux Christopher P. acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERMolineaux Christopher P. acquired 11.0k sh Restricted Stock Units — Director
2026-06-04INSIDERSCHIFF ANDREW N acquired 11.0k sh Restricted Stock Units — Director
2026-06-04INSIDERMehra Anand acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERMehra Anand acquired 11.0k sh Restricted Stock Units — Director
2026-06-04INSIDERSCHIFF ANDREW N acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERHumphries William D. acquired 42.4k sh Stock Option (Right to Buy) — Director
2026-06-04INSIDERHumphries William D. acquired 11.0k sh Restricted Stock Units — Director
2026-05-01 00:00 UTCINSIDER3 insider transactions — 2026-05 1 derivative
2026-05-01INSIDERHall Jesse Wayne transacted 9.3k sh — Chief Medical Officer ~$41k
2026-05-01INSIDERHall Jesse Wayne transacted 36.4k sh — Chief Medical Officer
2026-05-01INSIDERHall Jesse Wayne disposed of 36.4k sh Restricted Stock Units — Chief Medical Officer
2026-04-23 00:00 UTCINSIDER1 insider transaction — 2026-04 · net sell $1.4M
2026-04-23INSIDERLeonard Braden Michael sold 300.0k sh — 10% owner ~$1.36M
2026-03-01 00:00 UTCINSIDER3 insider transactions — 2026-03 1 derivative
Showing the 40 most recent of 61 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage